This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2009 Apr 9;458(7239):709-10.

doi: 10.1038/458709a.

Drug discovery: Fresh target for cancer therapy

Raymond J Deshaies

PMID: 19360071
DOI: 10.1038/458709a

Comment

Drug discovery: Fresh target for cancer therapy

Raymond J Deshaies. Nature. 2009.

. 2009 Apr 9;458(7239):709-10.

doi: 10.1038/458709a.

Author

Raymond J Deshaies

PMID: 19360071
DOI: 10.1038/458709a

No abstract available

PubMed Disclaimer

Comment on

An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer.
Soucy TA, Smith PG, Milhollen MA, Berger AJ, Gavin JM, Adhikari S, Brownell JE, Burke KE, Cardin DP, Critchley S, Cullis CA, Doucette A, Garnsey JJ, Gaulin JL, Gershman RE, Lublinsky AR, McDonald A, Mizutani H, Narayanan U, Olhava EJ, Peluso S, Rezaei M, Sintchak MD, Talreja T, Thomas MP, Traore T, Vyskocil S, Weatherhead GS, Yu J, Zhang J, Dick LR, Claiborne CF, Rolfe M, Bolen JB, Langston SP. Soucy TA, et al. Nature. 2009 Apr 9;458(7239):732-6. doi: 10.1038/nature07884. Nature. 2009. PMID: 19360080

Similar articles

Mechanisms of Cell Death and Disease: Advances in Therapeutic Intervention and Drug Discovery--ESH's Eighth International Conference. October 14-17, 2010, Cascais, Portugal.
Vucic D. Vucic D. IDrugs. 2010 Dec;13(12):836-9. IDrugs. 2010. PMID: 21154138
Editorial overview: cancer: from target discovery to targeted therapy: the risky business of target validation.
Cruzalegui F. Cruzalegui F. Curr Opin Pharmacol. 2014 Aug;17:iv-vi. doi: 10.1016/j.coph.2014.08.004. Epub 2014 Sep 15. Curr Opin Pharmacol. 2014. PMID: 25220882 No abstract available.
The protein-protein interactions as a target in medicinal chemistry and drug discovery.
Mustata G. Mustata G. Curr Top Med Chem. 2011;11(3):247. doi: 10.2174/156802611794072597. Curr Top Med Chem. 2011. PMID: 21320055 No abstract available.
Targeting CDK12 for Cancer Therapy: Function, Mechanism, and Drug Discovery.
Liu H, Liu K, Dong Z. Liu H, et al. Cancer Res. 2021 Jan 1;81(1):18-26. doi: 10.1158/0008-5472.CAN-20-2245. Epub 2020 Sep 21. Cancer Res. 2021. PMID: 32958547 Review.
Advancing cancer drug discovery towards more agile development of targeted combination therapies.
Carragher NO, Unciti-Broceta A, Cameron DA. Carragher NO, et al. Future Med Chem. 2012 Jan;4(1):87-105. doi: 10.4155/fmc.11.169. Future Med Chem. 2012. PMID: 22168166 Review.

See all similar articles

Cited by

Tumor burden negatively impacts protein turnover as a proteostatic process in noncancerous liver, heart, and muscle, but not brain.
Brown JL, Lawrence MM, Borowik A, Oliver L, Peelor FF 3rd, Van Remmen H, Miller BF. Brown JL, et al. J Appl Physiol (1985). 2021 Jul 1;131(1):72-82. doi: 10.1152/japplphysiol.01026.2020. Epub 2021 May 20. J Appl Physiol (1985). 2021. PMID: 34013745 Free PMC article.
In Search of a Cure for Proteostasis-Addicted Cancer: A AAA Target Revealed.
Xia D, Ye Y. Xia D, et al. Cancer Cell. 2015 Nov 9;28(5):550-552. doi: 10.1016/j.ccell.2015.10.006. Cancer Cell. 2015. PMID: 26555170 Free PMC article.
Multimodal mechanism of action for the Cdc34 acidic loop: a case study for why ubiquitin-conjugating enzymes have loops and tails.
Ziemba A, Hill S, Sandoval D, Webb K, Bennett EJ, Kleiger G. Ziemba A, et al. J Biol Chem. 2013 Nov 29;288(48):34882-96. doi: 10.1074/jbc.M113.509190. Epub 2013 Oct 15. J Biol Chem. 2013. PMID: 24129577 Free PMC article.
Ubiquitin turnover and endocytic trafficking in yeast are regulated by Ser57 phosphorylation of ubiquitin.
Lee S, Tumolo JM, Ehlinger AC, Jernigan KK, Qualls-Histed SJ, Hsu PC, McDonald WH, Chazin WJ, MacGurn JA. Lee S, et al. Elife. 2017 Nov 13;6:e29176. doi: 10.7554/eLife.29176. Elife. 2017. PMID: 29130884 Free PMC article.
Protein-protein interaction modulators: advances, successes and remaining challenges.
Mabonga L, Kappo AP. Mabonga L, et al. Biophys Rev. 2019 Aug;11(4):559-581. doi: 10.1007/s12551-019-00570-x. Epub 2019 Jul 12. Biophys Rev. 2019. PMID: 31301019 Free PMC article. Review.

See all "Cited by" articles

References

1. Oncologist. 2003;8(6):508-13 - PubMed
1. Nature. 1993 Jul 8;364(6433):161-4 - PubMed
1. Cell. 2004 Jan 23;116(2):181-90 - PubMed
1. Nature. 2003 Mar 20;422(6929):330-4 - PubMed
1. Nature. 2009 Apr 9;458(7239):732-6 - PubMed

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions

Grants and funding

R01 GM065997/GM/NIGMS NIH HHS/United States

LinkOut - more resources

Full Text Sources
- Nature Publishing Group
- Ovid Technologies, Inc.